Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk.

ABSTRACT: Demyelinating diseases, particularly multiple sclerosis (MS), present a unique therapeutic challenge in the management of inflammatory bowel disease (IBD). Although rare, the co-occurrence of IBD and demyelinating disorders is well-documented and may reflect shared immune, genetic, and environmental risk factors. As the therapeutic landscape of IBD expands to include biologics and small molecules that target immune pathways also implicated in MS, concerns around neurological safety have grown. In particular, anti-tumor necrosis factor agents have been consistently linked to new-onset or worsening demyelinating events, while other treatments such as sphingosine-1-phosphate receptor modulators and natali-zumab are licensed for both IBD and MS, though real-world data in patients with coexisti

SUBMITTER: Honap S 

PROVIDER: S-EPMC12803786 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature